HIV drug development: the next 25 years

被引:242
作者
Flexner, Charles
机构
[1] Johns Hopkins Univ, Dept Med, Div Clin Pharmacol & Infect Dis, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Div Clin Pharmacol & Infect Dis, Baltimore, MD 21287 USA
[3] Johns Hopkins Univ, Dept Int Hlth, Div Clin Pharmacol & Infect Dis, Baltimore, MD 21287 USA
关键词
D O I
10.1038/nrd2336
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The development of drugs for HIV infection began soon after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to manage this disease. Here we review the current treatment options, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. With a view to the next quarter century, we consider whether drug resistance can be avoided, which drug classes will be favoured over others, which strategies are most likely to succeed, and the potential impact of pharmacogenomics and individualized therapy.
引用
收藏
页码:959 / 966
页数:8
相关论文
共 48 条
[1]  
[Anonymous], GUID US ANT AG HIV 1
[2]   A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome [J].
Benson, CA ;
Williams, PL ;
Currier, JS ;
Holland, F ;
Mahon, LF ;
MacGregor, RR ;
Inderlied, CB ;
Flexner, C ;
Neidig, J ;
Chaisson, R ;
Notario, GF ;
Hafner, R .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) :1234-1243
[3]   APOBEC-mediated editing of viral RNA [J].
Bishop, KN ;
Holmes, RK ;
Sheehy, AM ;
Malim, MH .
SCIENCE, 2004, 305 (5684) :645-645
[4]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[5]  
COOPER D, 14 C RETR OPP INF WE
[6]  
De Gruttola V, 2006, AIDS RES HUM RETROV, V22, P1106, DOI 10.1089/aid.2006.22.1106
[7]   Once-daily versus twice-daily Lopinavir/Ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial [J].
Eron, JJ ;
Feinberg, J ;
Kessler, HA ;
Horowitz, HW ;
Witt, MD ;
Carpio, FF ;
Wheeler, DA ;
Ruane, P ;
Mildvan, D ;
Yangco, BG ;
Bertz, R ;
Bernstein, B ;
King, MS ;
Sun, E .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (02) :265-272
[8]   Class of antiretroviral drugs and the risk of myocardial infarction [J].
Friis-Moller, Nina ;
Reiss, Peter ;
Sabin, Caroline A. ;
Weber, Rainer ;
Monforte, Antonella d'Arminio ;
El-Sadr, Wafaa ;
De Wit, Stephane ;
Kirk, Ole ;
Fontas, Eric ;
Law, Matthew G. ;
Phillips, Andrew ;
Lundgren, Jens D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (17) :1723-1735
[9]   Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV [J].
Gallant, JE ;
DeJesus, E ;
Arribas, JR ;
Pozniak, AL ;
Gazzard, B ;
Campo, RE ;
Lu, B ;
McColl, D ;
Chuck, S ;
Enejosa, J ;
Toole, JJ ;
Cheng, AK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03) :251-260
[10]   Towing of sensory axons by their migrating target cells in vivo [J].
Gilmour, D ;
Knaut, H ;
Maischein, HM ;
Nüsslein-Volhard, C .
NATURE NEUROSCIENCE, 2004, 7 (05) :491-492